抗p75 NGF Receptor / CD271抗体 | Anti-p75 NGF Receptor / CD271 antibody

• 特長
• 価格
• DATA IMAGES
• 製品情報
• APPLICATION
• PROPERTIES
• TARGET

特長

• 高品質の抗体です。
• 幅広い研究分野に関連する抗体を取り揃えています。
• 使用されたアプリケーションや動物種などの情報が充実しています。
• 多数の論文で使用実績がある信頼性の高い抗体です。

目次に戻る

価格

目次に戻る

DATA IMAGES

WB analysis of (A)25, (B)50, and (C)100 ng purified recombinant human nerve growth factor receptor (p75 NTR) using GTX42173 p75 NTR antibody.

目次に戻る

製品情報

Host	Rabbit
Clonality	Polyclonal
Isotype	IgG
Application	WB, IHC-Fr
Reactivity	Human, Mouse

目次に戻る

APPLICATION

Application Note

*Optimal dilutions/concentrations should be determined by the researcher.

Application	Dilution
WB	1μg/ml
IHC-Fr	Assay dependent
Note : WB This antibody detects a band of approximately 75-80kDa in A-20 cell lysate.

Not tested in other applications.

Calculated MW	45 kDa. ( Note )

目次に戻る

PROPERTIES

Form	Liquid
Buffer	PBS, 0.02% Sodium Azide
Storage	Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration	1.0 mg/ml (Please refer to the vial label for the specific concentration.)
Antigen Species	Human
Immunogen	Recombinant human p75 NGF Receptor / CD271.
Purification	Purified by affinity chromatography
Conjugation	Unconjugated
Note	For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.

目次に戻る

TARGET

Synonyms	Nerve Growth Factor Receptor , Cd271 , Gp80-Lngfr , Tnfrsf16 , P75(Ntr) , P75Ntr , Ngfr
Background	Nerve growth factor receptor contains an extracellular domain containing four 40-amino acid repeats with 6 cysteine residues at conserved positions followed by a serine/threonine-rich region, a single transmembrane domain, and a 155-amino acid cytoplasmic domain. The cysteine-rich region contains the nerve growth factor binding domain. [provided by RefSeq, Jul 2008]
Database	・ Gene ID: 4804 ・ UniProt: P08138

目次に戻る